Showing 2181-2190 of 5771 results for "".
- USRetina Announces RetinaOS To Help Practices Better Understand and Manage Business Efficientlyhttps://modernod.com/news/usretina-announces-retinaos-to-help-retina-practices-understand-and-manage-the-business-efficiently/2477257/USRetina announced new technology offerings it says will drive more value for retina practices. USRetina’s new cloud-based platform, known as RetinaOS, includes RetinaInventory, an inventory management and practice data consolidation solution, and RetinaPurchasing, a group purchasing portal that
- USRetina Announces Changes to Senior Management Teamhttps://modernod.com/news/usretina-announces-changes-to-senior-management-team/2477256/USRetina, an independent provider of technology and services specific to retina practices, announced that it has expanded its leadership team with the appointment of a new executive team. The change reflects a strategic approach to long-term value and growth for the organization, according to the
- Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for DR and DME from Apexian Pharmaceuticalshttps://modernod.com/news/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-dr-and-dme-from-apexian-pharmaceuticals/2477254/Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first
- Tangible Science Announces Timing for Tangible Boost Launchhttps://modernod.com/news/tangible-science-announces-timing-for-tangible-boost-launch/2477250/Tangible Science recapped its 2019 accomplishments and announced the expected launch timing for its new conditioning solution, Tangible Boost. In 2019, the company developed agreements and collaborated with SynergEyes, Contamac, Bausch+Lomb, Paragon Vision Sciences, and Acuity Polymers to
- Covenant Surgical Partners Rebrands Company, Announces Partnership With Texas Eye Care Networkhttps://modernod.com/news/covenant-surgical-partners-rebrands-company-announces-partnership-with-texas-eye-care-network/2477246/Signaling its evolution from an ambulatory surgery center company to a physician services organization, Covenant Surgical Partners has rebranded to Covenant Physician Partners. In addition, the company announced it has completed its partnership with Texas Eye Care Network. Covenant’s shift
- Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-announces-first-patient-enrolled-in-the-phase-3-invigorate-trial-in-allergic-conjunctivitis/2477243/Aldeyra Therapeutics announced enrollment of the first patient into the phase 3 INVIGORATE trial of topical ocular reproxalap in patients with allergic conjunctivitis. “Initiating enrollment in the INVIGORATE trial moves us closer to our goal of providing allergic conjunctivitis patients w
- Aerie Pharmaceuticals Announces FDA Approval of its Athlone, Ireland Facility for Production of Rocklatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-fda-approval-of-its-athlone-ireland-facility-for-production-of-rocklatan/2477245/Aerie Pharmaceuticals announced that its sterile fill production facility in Athlone, Ireland has received approval from FDA to produce Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the U.S. market. The regulatory clearance of the plant follows a successful preapprov
- Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-for-dry-eye-disease/2477235/Neuroptika announced that the first patient was enrolled in a phase 2 clinical trial of NRO-1 for the treatment of dry eye disease. NRO-1 is a novel therapeutic with the potential to protect and regenerate corneal nerves in ophthalmic diseases. “Existing treatments for dry eye diseas
- IrisVision and Samsung Announce Partnership to Roll Out Vision Correction Software Platformhttps://modernod.com/news/irisvision-and-samsung-announce-partnership-to-roll-out-vision-correction-software-platform/2477229/Samsung Electronics and IrisVision announced a strategic partnership to roll out IrisVision’s technology worldwide. IrisVision’s vision correction software platform utilizes the power of Samsung’s industry leading Galaxy smartphones and XR devices and mobile AI platform to enable people
- Bionic Vision Technologies Announces Interim Pilot Study Results of the BVT Bionic Eye Systemhttps://modernod.com/news/bionic-vision-technologies-announces-interim-pilot-study-results-of-the-bvt-bionic-eye-system/2477228/Bionic Vision Technologies announced interim results of a pilot study involving 4 patients with late-stage retinitis pigmentosa (RP) implanted with a visual prosthesis designed to improve awareness of external objects